一种与同类静脉制剂等效的银杏达莫口服制剂组合物制造技术

本发明专利技术提供一种与同类静脉制剂临床等效的银杏达莫口服制剂组合物，所含两种主药银杏叶提取物、双嘧达莫酸化物的重量比为１∶１～４，除主药外，还含有维生素类、谷胱甘肽、叶酸等作为抗氧化剂，还可进一步含有粘合剂、助流剂、崩解剂、填充剂等常用药用辅料。所得制剂可以是片剂、胶囊、颗粒剂、滴丸、软胶囊、口服液等口服制剂。与市场现有制剂银杏达莫注射液相比，本发明专利技术制剂的产品质量可控性、稳定性好，保存期长，临床使用方便。

Ginkgo dipyridamole oral preparation composition equivalent to same vein preparation

The invention provides a Yinxingdamo oral preparation equivalent to similar intravenous preparation, containing two main drugs ginkgo leaf extract and dipyridamole glucuronide in the weight ratio of 1: 1 to 4, in addition to the main medicine, also contains vitamins, glutathione and folic acid as an antioxidant, also can further contain adhesive, glidants, disintegrating agents, fillers and other commonly used medicinal materials. The preparation can be an oral preparation such as tablets, capsules, granules, pills, soft capsules, oral liquid, etc.. Compared with the existing market preparation Ginkgo Leaf Extract and Dipyridamole Injection, the preparation of the invention has the advantages of controllable quality, good stability, long storage period and convenient clinical use.

【技术实现步骤摘要】

【技术保护点】
一种与同类静脉制剂等效的银杏达莫口服制剂组合物，其特征在于，主药银杏叶提取物（以银杏总黄酮计）与双嘧达莫酸化物的重量比为１∶１～４，银杏叶提取物（以银杏总黄酮计）与抗氧化剂的重量比５～２０∶１。

【技术特征摘要】

【专利技术属性】
技术研发人员：安英，张玲玲，张慧英，陈华，
申请(专利权)人：北京瑞伊人科技发展有限公司，安英，
类型：发明
国别省市：11[中国|北京]